Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy
Open Access
- 30 October 2012
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 11 (1) , 143
Abstract
Omega-3 fatty acids are important in treatment of severe primary hypertriglyceridemia (HTG). In 15 patients with severe primary HTG (TG >500 mg/dl despite conventional TG lowering therapy), we assessed efficacy-safety of sequential monthly treatment with Lovaza, 4 to 8 to 12 g/day. With TG >500 mg/dl despite Type V diet, hyperinsulinemia and diabetes control, and fibric acids, Lovaza (4 g/d) was added for 1 month, and if TG remained >500 mg/dl, increased to 8 g/d for 1 month, and then to 12 g/d for 1 month, and subsequently reduced to 4 g/day for 4 months. Primary HTG, median TG 884 mg/dl, 14 men, 1 woman, all white, age 50 ± 7 years, 12 non-diabetic, 3 with stable diabetes control. Weight and diet held stable throughout. In 5 patients, after 1, 2, and 3 months on 4 g/day, TG fell <500, mean 1390 to 234 (−83%, p<.0001), to 135 (−90%, p<.0001), and 158 mg/dl (−89%, p<.0001), with a negative TG slope, p=.0013. Non-HDLC fell from 320 to 177 (−45%, p=.001), to 152 (−53%, p=.0002), and to 163 (−49%, p=.0004), with a negative slope, p=.01. In 10 patients, with Lovaza increased from 4 to 8 to 12 g, 3 failed to respond. In 7 of these 10 patients, TG fell 37% from 1075 to 672 on 4 g (p=.006), to 577 on 8 g (−46%, p=.0009), and to 428 mg/dl (−60%, p<.0001) on 12 g/day, with a negative TG slope, p=.0018. TG on 12 g/day was lower than on 8 g/day, p =.03. Non-HDLC fell from 245 to 217 mg/dl (−11%) on 4 g/day, to 203 (−17%, p=.01) on 8 g/day, and to 192 (−22%, p=.003) on 12 g/day, with a negative slope, p=.016. Compared to pre-Lovaza baseline, no abnormal measures developed in safety tests. The 4, 8, and 12 g/d Lovaza doses were well tolerated. Titration of Lovaza from 4 to 8 to 12 g/d safely offers an effective way to lower TG beyond conventional 4 g therapy.Keywords
This publication has 31 references indexed in Scilit:
- Independent and Combined Effects of Exercise Training and Metformin on Insulin Sensitivity in Individuals With PrediabetesDiabetes Care, 2011
- Novel developments in omega-3 fatty acid-based strategiesCurrent Opinion in Lipidology, 2011
- Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitusCurrent Opinion in Lipidology, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Prescription Omega-3-Acid Ethyl Esters for the Treatment of Very High TriglyceridesPostgraduate Medicine, 2009
- Extended‐release niacin decreases serum fetuin‐A concentrations in individuals with metabolic syndromeDiabetes/Metabolism Research and Reviews, 2009
- Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed DyslipidemiaThe American Journal of Cardiology, 2008
- Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjectsLipids in Health and Disease, 2007
- The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or FenofibrateJournal of Cardiovascular Pharmacology and Therapeutics, 2006
- Diabetic dyslipidemiaThe American Journal of Cardiology, 1998